Startseite Kongressberichte 2021 63rd ASH Annual Meeting and Exposition In-Person/Virtual Multiple Myeloma Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance: What We Have and What We Want

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want

151
Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Sigrun Thorsteinsdottir, Gauti Kjartan Gislason, Thor Aspelund, et al.

See abstract for more info.

 

152
High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study

Habib El-Khoury, Jean-Baptiste Alberge, Hadley Barr, et al.

See abstract for more info.

 

153
Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, et al.

See abstract for more info.

 

154
Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM)

Sæmundur Rögnvaldsson, Elias Eythorsson, Sigrun Thorsteinsdottir, et al.

See abstract for more info.

 

155
A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Andrew Staron, Luke Zheng, Gheorghe Doros, et al.

See abstract for more info.

 

156
Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Sigurdur Y Kristinsson, Sæmundur Rögnvaldsson, Sigrun Thorsteinsdottir, et al.

See abstract for more info.